Study shows benefits of CGM in adults with diabetes who take multiple daily injections

DexCom, Inc., the leader in continuous glucose monitoring (CGM) for people with diabetes, is presenting important clinical data for patients with type 1 and type 2 diabetes, at the American Diabetes Association's 77th Scientific Sessions, June 9-13 in San Diego, California.

The new data is the result of combined type 1 and type 2 cohorts from the DIaMonD study (Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes) and demonstrates the impact of CGM on A1C, hyperglycemia and hypoglycemia in adults with either type 1 or type 2 diabetes who choose to take multiple daily injections of insulin in lieu of other methods of insulin delivery. The study showed DexCom CGM System users achieved a 0.9 percent average A1C reduction after 24 weeks of regular use, compared to 0.5 percent in the Usual Care group that relied only on fingerstick blood glucose measurements. The benefits in glycemic control were seen even in study participants using CGM that had large decreases in the number of fingersticks.

Additional highlights include:

  • Strong adherence to CGM in adults with both type 1 and type 2 diabetes regardless of age, education or numeracy.
  • Ninety-three percent were using CGM more than six days a week in month six.
  • Consistent A1C reductions in all subgroups.
  • Time in range increased, while times in hypoglycemia and hyperglycemia decreased.
  • Patients with both type 1 and type 2 diabetes frequently interact with their CGM display device, providing greater glucose awareness and better informing their diabetes management decisions.

"This new data represents another important milestone in a blockbuster year for the advancement of diabetes management," said Kevin Sayer, President and CEO of DexCom. "As the first and only therapeutic CGM approved by Medicare for patients age 65 or older, DexCom G5 Mobile is setting a new standard of care for a wide spectrum of patients."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Genetic and environmental drivers shape early type 1 diabetes risk in children